221 related articles for article (PubMed ID: 24896842)
1. New investigational drugs for the treatment of neuropathic pain.
Sałat K; Kowalczyk P; Gryzło B; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2014 Aug; 23(8):1093-104. PubMed ID: 24896842
[TBL] [Abstract][Full Text] [Related]
2. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development.
Pexton T; Moeller-Bertram T; Schilling JM; Wallace MS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1277-84. PubMed ID: 21740292
[TBL] [Abstract][Full Text] [Related]
3. Novel sodium channel antagonists in the treatment of neuropathic pain.
Rivara M; Zuliani V
Expert Opin Investig Drugs; 2016; 25(2):215-26. PubMed ID: 26576738
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
Rice AS; Smith MT
Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
Smith MT; Muralidharan A
Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
[TBL] [Abstract][Full Text] [Related]
6. Sigma-1 receptors and animal studies centered on pain and analgesia.
Davis MP
Expert Opin Drug Discov; 2015; 10(8):885-900. PubMed ID: 26037105
[TBL] [Abstract][Full Text] [Related]
7. Challenges relating to the therapeutic management of neuropathic pain.
Alcántara Montero A; González Curado A
Rev Esp Anestesiol Reanim (Engl Ed); 2019 Oct; 66(8):452-453. PubMed ID: 31153594
[No Abstract] [Full Text] [Related]
8. Discontinued neuropathic pain therapy between 2009-2015.
Knezevic NN; Cicmil N; Knezevic I; Candido KD
Expert Opin Investig Drugs; 2015; 24(12):1631-46. PubMed ID: 26472477
[TBL] [Abstract][Full Text] [Related]
9. Zucapsaicin for the treatment of neuropathic pain.
Sałat K; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2014 Oct; 23(10):1433-40. PubMed ID: 25171227
[TBL] [Abstract][Full Text] [Related]
10. Emerging trends in the management of neuropathic pain.
McCleane G
Expert Rev Neurother; 2005 Sep; 5(5):617-23. PubMed ID: 16162085
[TBL] [Abstract][Full Text] [Related]
11. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
Muralidharan A; Wyse BD; Smith MT
Pain Med; 2014 Jan; 15(1):93-110. PubMed ID: 24433468
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for neuropathic pain.
Gilron I; Dickenson AH
Expert Opin Emerg Drugs; 2014 Sep; 19(3):329-41. PubMed ID: 24793304
[TBL] [Abstract][Full Text] [Related]
13. Recent trends in neuropathic pain patents.
Maia RD
Expert Opin Ther Pat; 2017 May; 27(5):539-546. PubMed ID: 27998196
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.
Papanas N; Ziegler D
Expert Opin Emerg Drugs; 2016 Dec; 21(4):393-407. PubMed ID: 27813425
[TBL] [Abstract][Full Text] [Related]
15. Ion channel blockers for the treatment of neuropathic pain.
Colombo E; Francisconi S; Faravelli L; Izzo E; Pevarello P
Future Med Chem; 2010 May; 2(5):803-42. PubMed ID: 21426204
[TBL] [Abstract][Full Text] [Related]
16. Sodium channel blockers for neuropathic pain.
Zuliani V; Rivara M; Fantini M; Costantino G
Expert Opin Ther Pat; 2010 Jun; 20(6):755-79. PubMed ID: 20384535
[TBL] [Abstract][Full Text] [Related]
17. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.
Kushnarev M; Pirvulescu IP; Candido KD; Knezevic NN
Expert Opin Investig Drugs; 2020 Mar; 29(3):259-271. PubMed ID: 32070160
[No Abstract] [Full Text] [Related]
18. Investigational drugs for pruritus.
Benecke H; Lotts T; Ständer S
Expert Opin Investig Drugs; 2013 Sep; 22(9):1167-79. PubMed ID: 23815605
[TBL] [Abstract][Full Text] [Related]
19. Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
Smith MT; Wyse BD; Edwards SR
Pain Med; 2013 May; 14(5):692-705. PubMed ID: 23489258
[TBL] [Abstract][Full Text] [Related]
20. Anti-allodynic effect of 2-(aminomethyl)adamantane-1-carboxylic acid in a rat model of neuropathic pain: a mechanism dependent on CaV2.2 channel inhibition.
Zoidis G; Sandoval A; Pineda-Farias JB; Granados-Soto V; Felix R
Bioorg Med Chem; 2014 Mar; 22(6):1797-803. PubMed ID: 24582401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
